Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea

Lung

Volumn 191, Issue 5, 2013, Pages 565-571

  Lee, Sang Kook ^a   Kim, Song Yee ^a   Kim, Eun Young ^a   Jung, Ji Ye ^a   Park, Moo Suk ^a   Kim, Young Sam ^a   Kim, Se Kyu ^a   Chang, Joon ^a   Kang, Young Ae ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Mycobacterium tuberculosis; Nontuberculous mycobacterium; Tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; CLARITHROMYCIN; ETANERCEPT; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; RIFAMPICIN;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CROHN DISEASE; FEMALE; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX; SOUTH KOREA; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RECEPTORS, TUMOR NECROSIS FACTOR; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84884816068     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9481-5     Document Type: Article

References (29)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594-1602
2. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P (2005) BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 44(7):939-947
3. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462-2476
4. Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP (2006) Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 24(5):587-593
5. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8(10):601-611
6. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Scholvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185-1206
7. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261-1265
8. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM (2008) Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 46(11):1738-1740
9. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34(4):706-711
10. Mankia S, Peters JE, Kang S, Moore S, Ehrenstein MR (2011) Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol 30(3):399-401
11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522-528
12. Taiwo B, Glassroth J (2010) Nontuberculous mycobacterial lung diseases. Infect Dis Clin North Am 24(3):769-789
13. McGrath EE, Blades Z, McCabe J, Jarry H, Anderson PB (2010) Nontuberculous mycobacteria and the lung: from suspicion to treatment. Lung 188(4):269-282
14. Arend SM, van Soolingen D, Ottenhoff TH (2009) Diagnosis and treatment of lung infection with nontuberculous mycobacteria. Curr Opin Pulm Med 15(3):201-208
15. van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D (2008) Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol 4(12):649-656
16. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ (2005) Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293(22):2756-2761
17. Ryoo SW, Shin S, Shim MS, Park YS, Lew WJ, Park SN, Park YK, Kang S (2008) Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans. J Clin Lab Anal 22(6):415-420
18. Lee SK, Lee EJ, Kim SK, Chang J, Jeong SH, Kang YA (2012) Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scand J Infect Dis 44(10):733-738
19. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4):367-416
20. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122-2127
21. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098-1104
22. Mootoo A, Stylianou E, Arias MA, Reljic R (2009) TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 8(1):53-62
23. Lin PL, Plessner HL, Voitenok NN, Flynn JL (2007) Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 12(1):22-25
24. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann Rheum Dis 71(2):231-237
25. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA (2009) Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15(10):1556-1561
26. Piersimoni C (2012) Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis 31(4):397-403
27. Iseman MD (2011) Mycobacterial infections in the era of modern biologic agents. Am J Med Sci 341(4):278-280
28. Bala S, Hastings KL, Kazempour K, Inglis S, Dempsey WL (1998) Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 42(9):2336-2341
29. Levin M, Newport MJ, D'Souza S, Kalabalikis P, Brown IN, Lenicker HM, Agius PV, Davies EG, Thrasher A, Klein N et al (1995) Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet 345(8942):79-83